hepatocellular carcinoma
Conditions
Interventions
experimental group:Facal microbiota transplantation
Sponsors
Mianyang Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Confirmed by clinical examination for liver cancer, liver cancer and diseases in Barcelona centre (BCLC) staging standard display as late, does not apply to patients with surgical treatment, patients survival time is expected to more than 3 months (based on the tumor type, stage, estimated lifetime comprehensive judgment), signed informed consent, research hospital ethics committee approval.
Exclusion criteria
Exclusion criteria: (1) Pregnant or lactating women; Drug users; Suspected or confirmed history of alcohol/drug abuse; (2) Previous history of abdominal surgery; (3) Having a disease that may cause impairment of gastrointestinal function. Such as diabetes, thyroid diseases, intestinal obstruction, Inflammatory bowel disease (IBD), etc. (4) Take antibiotics, non-steroidal anti-inflammatory drugs, microecological agents, gastrointestinal motional drugs, acid-inhibiting drugs and other drugs that affect intestinal flora 2 weeks before treatment; (5) A history of Spontaneous bacterial peritonitis (SBP) combined with gastrointestinal bleeding or Spontaneous bacterial peritonitis two weeks ago; (6) Other serious diseases (including serious infections, serious heart, kidney, respiratory, blood, endocrine, neuropsychiatric diseases) or other types of tumors; (7) A history of use of immunosuppressive agents, or other severe Immunodeficiency diseases, such as Human Acquired Immunodeficiency Virus (HIV) infection, rheumatic diseases, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms;Liver function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fecal flora;Adverse events; | — |
Countries
China
Contacts
Public ContactLi xiao an
Department of Gastroenterology, Mianyang Central Hospital
Outcome results
None listed